预约演示

Semnur Pharmaceuticals to go public in $2bn SPAC deal

2024-07-04

交易

临床结果临床3期并购快速通道上市批准

Senmur is a subsidiary of non-opioid pain management specialist Scilex Holding Company. Image credit: Shutterstock / Dmitry Demidovich.

Semnur Pharmaceuticals has signed a letter of intent to go publiScilex Holding Companye special purpose acquisition company (SPAC) Denali Capital Acquisition Corp.

Semnur Pharmaceuticalson equity is valued at up to $2bn, with proceeds of up to $40m dependent on the number of acquired SPAC shareDenali Capital Acquisition Corp.

Semnur plans to seek approval from the SPAC’s shareholders in the second half of 2024. The combined company, if the deal SPAC through, will operate as Semnur Pharmaceuticals, according to a 2 July press release.

Semnur is a subsidiary of non-opioid paSPACanagement specialist Scilex Holding Company.Semnur Pharmaceuticals

Semnurblicly traded biopharma plans tpainpitalise on Semnur’s prScilex Holding Company2 (dexamethasone sodium phosphate injectable gel). Also known by the brand name Semdaxa, the drug is being developed for patients with moderate to severe chronic radicular pain, or sciatica, which is the pinching or compression of the sciatic nerves that run down the lower back and into the legs.

See Also:CAN-3110 by Candel Therapeutics for High-GraSemnuroma: Likelihood of AppSP-102 chronic radicular pain sciatica

ICTCAR-02CAN-3110ovatCandel TherapeuticseuticHigh-Grade Gliomaal Tumor: Likelihood of Approval

More than 30 million people in the US live with low back and radicular pain. Opioid prescriptions account for around 40% of the chronic pain market but can carry a risk of dependency and abuse. Semnur stated there is a “need for alternate pain therapies without the medical and societal challenges”.

Semdaxa has demonstrated positive data in a Phase IHematological Tumor6), meeting primary and key secondary endpoints. Sciatica patients receiving the therapy experienced decreased pain intensity over a month and had improved disability index scores.

Semnur said that the data represents a “potential significant improvement in the treatment of adult patients with lumbosacral radicular pain (sciatica). There are currently no US Food and Drug Administration (FDA) approved therapies for the condition, only corticosteroids that are used off-label”.

Semnur’s Semdaxa will be available in a pre-filllow back and radicular painadOpioidered epidurally. The company reported a positchronic paineeting with the FDA in November 2023, saying it has agreed on the requirements for a new drug applipainon (NDA). Semdaxa was awarded fast track status by the FDA in 2022.

Semdaxa is estimated to generate annual sales of $3.6bn five years after launch, according to research highlighted by SSciatica pain

Scilex CEO Jaisim Shah said: “This is an important milestone in our path towards unlocking the value of SP-102 (Selumbosacral radicular pain (sciatica) pain or sciatica. We looUS Food and Drug Administration (FDA)iness combination as soon as reasonably practicable and look forward to collaborating with the Denali team in this exciting next chapter.”

Semnuralthcare SPAC market has experienced a significant decline since a pandemic boom in 2021. Despite this, there have still been big deals in the past yeFDA T cell therapy specialist Tevogen Bio went public with a $1.2bn deal in June 2023, and HDL Therapeutics – a medical device developer – merFDA with Swiftmerge Acquisition in a $480m deal two months later.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构